Search Result

Results for "

ROCK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ROCK (128) ADC Payload (1) Akt (1) Apoptosis (9) Autophagy (8) Biochemical Assay Reagents (1) Calcium Channel (7) Cdc42-binding kinase (1) CDK (1) Drug Metabolite (1) Endogenous Metabolite (2) ERK (3) G Protein-coupled Receptor Kinase (GRK) (9) GPR55 (1) GSK-3 (1) HDAC (2) HIV (4) HSP (1) IGF-1R (1) Isotope-Labeled Compounds (2) JNK (1) LIM Kinase (LIMK) (4) Mas-related G-protein-coupled Receptor (MRGPR) (1) MMP (1) Monoamine Transporter (1) Myosin (4) Opioid Receptor (1) Organoid (4) p38 MAPK (4) PKA (12) PKC (18) Ras (1) Reference Standards (2) Ribosomal S6 Kinase (RSK) (3) SGK (2) Small Interfering RNA (siRNA) (6) STAT (2)
By Research Areas:	Cancer (64) Cardiovascular Disease (36) Endocrinology (3) Inflammation/Immunology (32) Metabolic Disease (4) Neurological Disease (28)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (6)

148

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: ROCK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119937

ROCK inhibitor-2 2 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC₅₀ values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC₅₀ of 75 nM. ROCK inhibitor-2 exhibits antitumor activity .

HY-153011

ROCK-IN-5	ROCK ERK GSK-3	Cardiovascular Disease Neurological Disease
ROCK-IN-5 (compound I-B-37) is a potent inhibitor of *ROCK, ERK, GSK, and AGC* protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research .

HY-U00351

ROCK-IN-1 1 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK-IN-1 is a potent inhibitor of *ROCK, with an IC₅₀* of 1.2 nM for ROCK2.

HY-116238

ROCK-IN-D2	ROCK	Others
ROCK-IN-D2 is a potent and selective *ROCK* inhibitor .

HY-156593

ROCK-IN-9	ROCK	Cancer
ROCK-IN-9 (Compound T345) is a *ROCK* inhibitor. ROCK-IN-9 shows cytotoxicity in HepG2 cell, with an IC₅₀ of 40.8 μM. ROCK-IN-9 has good pharmacokinetic properties in mice, and shows high in vivo exposure and oral bioavailability at lower doses .

HY-149700

ROCK2-IN-7	ROCK MMP STAT	Others
ROCK2-IN-7 is a kinase inhibitor targeting to *ROCK2. ROCK2-IN-7 inhibits ROCK2/pSTAT3 Signaling. ROCK*2-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model .

HY-10833

ROCK-IN-10	ROCK	Cardiovascular Disease
ROCK-IN-10 (compound 50) is a potent *ROCK* inhibitor with IC₅₀ values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases .

HY-113641

ROCK-IN-32	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK-IN-32 is a *ROCK* inhibitor, with an IC₅₀ value of 11 nM for *ROCK2. ROCK*-IN-32 can be used in research of cardiovascular disease, cancer and inflammation .

HY-W295201

ROCK-IN-11	ROCK	Cancer
ROCK-IN-11 (example 94) is a potent inhibitor of *ROCK1* and *ROCK2, with the IC₅₀* of ≤ 5μM. ROCK-IN-11 plays an important role in cancer research .

HY-178013

ROCK2-IN-11	ROCK	Inflammation/Immunology
ROCK2-IN-11 (Compound A20) is a selective *ROCK2* inhibitor with an IC₅₀ of 0.18 μM for ROCK2 over ROCK1. ROCK2-IN-11 can be used for idiopathic pulmonary fibrosis and cGVHD research .

HY-Q22471

ROCK1-IN-1	ROCK	Cardiovascular Disease
ROCK1-IN-1 is a *ROCK1* inhibitor with a K_i value of 540 nM. ROCK1-IN-1 can be used for the research of hypertension, glaucoma and erectile dysfunction .

HY-175843

ROCK2-IN-10	ROCK STAT	Cancer
ROCK2-IN-10 is a potent and selective *ROCK2* inhibitor (IC₅₀ = 0.020 μM) with 41-fold selectivity over isoform ROCK1. ROCK2-IN-10 inhibits metastasis by disrupting the cytoskeleton, independent of proliferative suppression. ROCK2-IN-10 shows superior inhibitory potency against cancer cell metastasis, which closely related to the suppression of STAT3 phosphorylation. ROCK2-IN-10 can be used for breast cancer metastasis research .

HY-176133

ROCK-IN-12	ROCK	Inflammation/Immunology
ROCK-IN-12 (compound R3) is a selective *ROCK* inhibitor. ROCK-IN-12 can be used in the study of glaucoma .

HY-156592

ROCK2-IN-6	ROCK	Inflammation/Immunology
ROCK2-IN-6 (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-156592A

ROCK2-IN-6 hydrochloride	ROCK	Inflammation/Immunology
ROCK2-IN-6 hydrochloride (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-156550

ROCK-IN-8	ROCK	Inflammation/Immunology
ROCK-IN-8 (Example 4) is a *ROCK* inhibitor, with an IC₅₀ value less than 100 nM. ROCK-IN-8 has anti-inflammatory activity. ROCK-IN-8 can be used for research of respiratory and gastro-intestinal diseases .

HY-162798

ROCK2-IN-9	ROCK	Cancer
ROCK2-IN-9 (compound 7u) is a selective *ROCK2* inhibitor (IC₅₀=36.8 nM) with anticancer activity. ROCK2-IN-9 inhibits cancer cell migration and invasion by regulating multiple cellular activities of the actin cytoskeleton. ROCK2-IN-9 can be used in breast cancer research .

HY-153569

ROCK-IN-7	ROCK	Others
ROCK-IN-7 (compound 9) is a ROCK kinase inhibitor. ROCK-IN-7 can be used for research in ocular diseases (such as glaucoma and retinal diseases) .

HY-116420

ROCK2-IN-8	ROCK	Neurological Disease
ROCK2-IN-8 (Compound 1) is an orally active *ROCK2* inhibitor, with an IC₅₀ of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .

HY-151189

ROCK-IN-4	ROCK	Others
ROCK-IN-4 is a potent *ROCK* inhibitor maintaining NO releasing ability. ROCK-IN-4 reversibly depolymerizes F-actin, and suppresses mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be used for glaucoma or ocular hypertension research .

HY-145294

ROCK2-IN-5	ROCK	Neurological Disease
ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation .

HY-123484

ROCK-IN-D1	ROCK	Others
ROCK-IN-D1 serves as a highly effective and selective inhibitor of ROCK.

HY-103620

ROCK2-IN-2	ROCK	Inflammation/Immunology
ROCK2-IN-2 is a selective *ROCK2* inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC₅₀ of <1 μM.

HY-172177

ROCK/HDAC-IN-2	Apoptosis HDAC ROCK	Cancer
ROCK/HDAC-IN-2 (Compound C-9) is a *ROCK/HDAC* inhibitor, with IC₅₀ values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, *ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis* and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .

HY-168650

ROCK/HDAC-IN-1	ROCK HDAC	Inflammation/Immunology Cancer
ROCK/HDAC-IN-1 (Compound 10h) is an orally active *ROCK/HDAC* inhibitor. ROCK/HDAC-IN-1 inhibits ROCK1/2 (IC₅₀: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC₅₀: 9.09, 8.03, 6.26, 0.41, 7.69 nM). ROCK/HDAC-IN-1 stimulates the activation of DAMPs, specifically Calreticulin (CRT) exposure and HMGB1 release, indicating that it is a potential ICD inducer.. ROCK/HDAC-IN-1 has antiproliferative activity against breast cancer cells (IC₅₀: 0.37 μM for MDA-MB-231 cell), and inhibits tumor growth and activates T cells without apparent toxicity .

HY-153564

ROCK-IN-6	ROCK	Inflammation/Immunology
ROCK-IN-6 is a potent and selectiveROCK2 inhibitor with an IC₅₀ of 2.19 nM. ROCK-IN-6 is extracted from patent WO2021164351 A1, example 7, has the potential for glaucoma and retinal diseases research .

HY-RS12118

Rock2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
Rock2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rock2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock2 Mouse Pre-designed siRNA Set A Rock2 Mouse Pre-designed siRNA Set A

HY-RS12117

ROCK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
ROCK2 Human Pre-designed siRNA Set A contains three designed siRNAs for ROCK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROCK2 Human Pre-designed siRNA Set A ROCK2 Human Pre-designed siRNA Set A

HY-RS12114

ROCK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
ROCK1 Human Pre-designed siRNA Set A contains three designed siRNAs for ROCK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROCK1 Human Pre-designed siRNA Set A ROCK1 Human Pre-designed siRNA Set A

HY-RS12116

Rock1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rock1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rock1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock1 Rat Pre-designed siRNA Set A Rock1 Rat Pre-designed siRNA Set A

HY-RS12115

Rock1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
Rock1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rock1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock1 Mouse Pre-designed siRNA Set A Rock1 Mouse Pre-designed siRNA Set A

HY-RS12119

Rock2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
Rock2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rock2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock2 Rat Pre-designed siRNA Set A Rock2 Rat Pre-designed siRNA Set A

HY-10319

BAY-549 3 Publications Verification ROCK-IN-2; Azaindole 1; TC-S 7001	ROCK	Cardiovascular Disease
BAY-549 (Azaindole 1), a chemical probe, is an orally active and ATP-competitive *ROCK* inhibitor with IC₅₀s of 0.6 and 1.1 nM for human *ROCK-1* and *ROCK-2*, respectively .

HY-112362

3-(4-Pyridyl)indole ROCKout; 3-(4-Pyridinyl)-1H-indole; Rho Kinase Inhibitor III, ROCKout	ROCK	Inflammation/Immunology
3-(4-Pyridyl)indole (Rockout) is a Rho-kinase (ROCK) inhibitor, with an IC₅₀ of 25 μM. 3-(4-Pyridyl)indole can inhibit blebbing and cause dissolution of actin stress fibers in a wound healing assay .

HY-168596

*RhoA-ROCK-IN-1*	ROCK Apoptosis	Cancer
RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of *RhoA/ROCK. RhoA-ROCK-IN-1 can significantly inhibit cell proliferation, migration, and invasion, while promoting cell apoptosis. RhoA-ROCK-IN-1 demonstrates remarkable anticancer activity by inhibiting the RhoA/ROCK* pathway .

HY-156796

*Akt/ROCK-IN-1*	ADC Payload	Neurological Disease Cancer
Akt/ROCK-IN-1 (B12) is a dual inhibitor for Akt and ROCK, with the IC₅₀s of 0.023 nM and 1.47 nM, respectively. Akt/ROCK-IN-1 has antitumor activity for neuroblastoma .

HY-13300A

SR-3677 dihydrochloride	ROCK Autophagy	Cancer
SR-3677 dihydrochloride (compound 5) is a potent and selective *ROCK-I* and *ROCK-II* inhibitor with an IC₅₀ values of 56 nM and 3 nM .

HY-139170

CAY10746	ROCK	Metabolic Disease
CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC₅₀ values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) .

HY-107209

RKI-1313	ROCK	Cancer
RKI-1313 is a *ROCK* inhibitor with IC₅₀s of 34, 8 µM for ROCK 1 and ROCK 2, respectively. RKI-1313 shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growth .

HY-15392

Chroman 1 45+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 is a highly potent and selective *ROCK* inhibitor. Chroman 1 is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-15392A

Chroman 1 dihydrochloride 45+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 dihydrochloride is a highly potent and selective *ROCK* inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-19346

AR-13324 analog mesylate	ROCK	Others
AR-13324 analog mesylate is an analog of AR-13324. AR-13324 is an *ROCK* and norepinephrine transporter (NET) inhibitor .

HY-137436

Cotosudil	ROCK	Endocrinology
Cotosudil is a ROCK kinase inhibitor, which can be used for glaucoma or ocular hypertension research .

HY-16758

Verosudil AR-12286	ROCK	Neurological Disease
Verosudil (AR-12286) is a *ROCK* inhibitor. Verosudil has equal inhibitory activity against ROCK1 and ROCK2 (K_i: 2 nM). Verosudil is less selective for PKA, PKCT, MRCKA, and CAM2A (K_i: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil increases trabecular outflow capacity to reduce intraocular pressure. Verosudil is useful in the study of glaucoma and ocular hypertension .

HY-16758A

Verosudil hydrochloride AR-12286 hydrochloride	ROCK	Neurological Disease
Verosudil (AR-12286) hydrochloride is the hydrochloride form of Verosudil (HY-16758). Verosudil hydrochloride is a *ROCK* inhibitor. Verosudil hydrochloride has equal inhibitory activity against ROCK1 and ROCK2 (K_i: 2 nM). Verosudil hydrochloride is less selective for PKA, PKCT, MRCKA, and CAM2A (K_i: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil hydrochloride increases trabecular outflow capacity to reduce intraocular pressure. Verosudil hydrochloride is useful in the study of glaucoma and ocular hypertension .

HY-12798B

Netarsudil hydrochloride AR-13324 hydrochloride	ROCK	Cardiovascular Disease Neurological Disease
Netarsudil (AR-13324) hydrochloride is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil hydrochloride reduces intraocular pressure by inhibiting *ROCK*, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil hydrochloride is mainly used in the study of ocular hypertension and primary open-angle glaucoma .

HY-10068

Y-33075 hydrochloride Y-39983	ROCK	Neurological Disease
Y-33075 hydrochloride (Y-39983) is a selective *ROCK* inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC₅₀ of 3.6 nM.

HY-P990805

Anti-Human/Mouse GRP78 Antibody (C38)	HSP	Metabolic Disease Cancer
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .

HY-W047432

5-Nitro-1H-indazole-3-carbonitrile DL0805	ROCK	Cardiovascular Disease
5-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase(ROCK) inhibitor with an IC₅₀ of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715)-induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research .

HY-15687

SAR407899 hydrochloride 3 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15301

Nocarnickelamide B	Microorganisms Ketones, Aldehydes, Acids Source classification	ROCK Myosin
Nocarnickelamide B (Compound 2) is a linear peptide and *ROCK1/2* inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against *ROCK1* and *ROCK2* with IC₅₀s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .

HY-N12466

3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine	Alkaloids Microorganisms Source classification Indole Alkaloids	PKC p38 MAPK ROCK
3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine (Compound 7) is an inhibitor of protein kinases, with IC₅₀s of 0.092, 0.26, 0.77 μM for PKC-α, ROCK, ASK1. 3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine shows potent cytotoxicity against PC-3 cancer cells with an IC₅₀ value of 0.16 μM .

Cat. No.	Product Name	Chemical Structure

HY-15307S

Belumosudil-d7
Belumosudil-d₇ (KD025-d₇) is deuterium labeled Belumosudil. Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-W700452

Y-27632-d4 hydrochloride hydrate

Y-27632-d₄ hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks